The promotion of genetic engineering research and GM crops can help to overcome the future deficit of food production in India. Hunger, poverty, malnutrition etc. are significant problems that still need to be addressed. ‘The National Food Security Act, 2013’ is expected to resolve some of these challenges. Agricultural GDP needs to be augmented by an increase in food crop production. Policy and social considerations related to GM crops continue to be a popular debate in the country. The regulation of transgenic plant research is guided by several legislations in the country. Regulatory agency approvals impact commercialization of transgenic crops. As greater capacity continues to develop in transgenic research on plants in Asia one of the prime considerations is whether Indian legislation and regulation adequately promote transgenic plant research. The present study maps and analyses various legislations that are involved in the research and commercialization of transgenic crops. The framework suggested will serve as a ready reckoner for firms practicing in this area.
Abstract – The robotics industry is achieving a level of commercial maturity as evidenced by innovative products brought to market, and by the increasing pace of emerging robotics companies being acquired by larger players in a diversity of industries. However, there are challenges with accelerating the rate and scale of innovation in this industry. Our hypothesis is that while there are remaining technological challenges, the largest challenge is for the industry to adapt by exploitation of business models that focus more intently on validating product/market fit, building teams to span seamlessly from laboratory to market, and on developing creative structure and vehicles to provide the needed resources to commercialize. To this end, we suggest that the robotics field could adapt approaches from the emerging “business model playbook” that are now being used in the field of biotechnology. These industries do compare somewhat in that they are each technologically driven, have long, high- risk development cycles, and have the need for high levels of capital, compared to the software industry. In this paper we review what has been accomplished in biotechnology, and also suggest how these lessons could be implemented in the field of robotics.
Genetic engineering (GE) technologies can contribute to improve crop productivity and quality in Ethiopia. Adoption of commercialized insect resistance and herbicide tolerance technologies can help to protect major crops such as cotton, maize, sorghum and small cereals from their main insect pests or prevent heavy weed-inflicted loss. Moreover, key production constraints such as bacterial wilt of enset, late blight of potato, drought stress on crops like maize and wheat, lodging resistance on tef as well as low nutritive quality of native crops like enset and grasspea can be addressed by strengthening domestic GE research capacity and international collaboration. Cognizant of this potential, the Ethiopian government has made significant investment in modern biotechnology capacity building in the last decade. There has also been specific interest by cotton sector to boost its productivity by adopting insect resistance (Bt) technologies. However, the GE regulatory system based on the existing biosafety law is so stringent that it is not possible for the country to access useful technologies from abroad as well as initiate domestic GE research. Consequently, no GE experiment is approved so far, leaving the country at risk of missing out on the global GE revolution. To catch up and harness the benefits of GE technologies, the country needs to create conducive regulatory environment, strengthen domestic GE capacity and devise a farsighted strategy.
Transforming medical research findings into viable commercial enterprises is a persistent challenge. Ontario, Canada, has deployed several approaches that could be applied in other regions. The provincial government has created R&D tax incentives, investment funds and commercialization incubators, along with streamlining clinical trials regulatory processes, to increase speed-to-market for medical biotechnology innovations. By creating supportive government policies, providing seed capital, and promoting partnerships between research institutions and industry, Ontario helps start-ups such as ApneaDX and OtoSim attract follow-on funding and access markets.
In November 2013, the Jordan Food and Drug Administration, in partnership with the Center for Medicine in the Public Interest, held a seminar entitled, “Advancing the Safe Use of Drugs: Enhancing Regulatory Quality Control.” Attendees included members of the JFDA leadership as well as representatives of Jordan’s healthcare community (hospitals, pharmacists, pharmaceutical manufacturers, academics). The seminar began a strategic thinking process aimed at enhancing a regulatory environment that values pharmaceutical manufacturing quality, the importance of stakeholder involvement, the urgent role of pharmacovigilance, and greater harmonization with advanced regulatory practices. The goal was to develop realistic recommendations that can be implemented within existing authorities and resources; that serve the Jordanian public health; and enhance the stature and reputation of the JFDA as a regional reference and a global leader.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 16
Instant Access to Deep Knowledge on Small-Molecule
access to valuable datasets, including:
- Patent litigation
- Clinical trial information
- International patent data
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.All trademarks and applicant names
are the property of their respective owners or